Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2018

Open Access 01-12-2018 | Research article

Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study

Authors: Josep Maria Haro, François-Xavier Lamy, Bengt Jönsson, Martin Knapp, Mélanie Brignone, Hugo Caillou, Ylana Chalem, Lene Hammer-Helmich, Benoît Rive, Delphine Saragoussi

Published in: BMC Psychiatry | Issue 1/2018

Login to get access

Abstract

Background

Patients who require a switch in their antidepressant therapy may have different clinical profiles and treatment needs compared with patients initiating or maintaining a first-line antidepressant therapy.

Methods

The Prospective Epidemiological Research on Functioning Outcomes Related to Major depressive disorder (MDD) (PERFORM) study was a 2-year observational cohort study in outpatients with MDD in five European countries. Enrolled patients were either initiating or undergoing the first switch to an antidepressant monotherapy. Baseline data on patients’ clinical status, functioning, productivity, quality of life and medical-resource use were compared in a cross-sectional baseline analysis.

Results

A total of 1402 patients were enrolled, of whom 1159 (82.7%) provided analysable baseline data. The majority (78.7%) of the analysable population were initiating antidepressant treatment and most (83.6%) were enrolled and followed up by general practitioners. Compared with patients initiating antidepressants, those switching antidepressants (21.3%) tended to have more severe depressive symptoms, greater anxiety, worse health-related quality of life, greater functional impairment, greater medical-resource use and had a different medical history. Limitations included an over-representation of switches due to lack of efficacy among patients who were switching treatment, as patients were selected based on presence of depressive symptoms.

Conclusions

Patients with MDD who are switching treatment for the first time have a different profile and different depression-associated health needs compared with those initiating treatment. Therapeutic management should therefore be adapted for patients who switch.

Trial registration

ClinicalTrials.gov NCT01427439; Retrospectively registered 26 August 2011.
Appendix
Available only for authorised users
Literature
1.
2.
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.CrossRefPubMed
3.
Souery D, Amsterdam J, De Montigny C, Lecrubier Y, Montgomery S, Lipp O, et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91.CrossRefPubMed
4.
Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al.; STAR*D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163(1):28–40.
5.
6.
Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ. World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–85.CrossRefPubMed
7.
Möller HJ, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S. European Psychiatric Association. Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. Eur Psychiatry. 2012;27(2):114–28.
8.
9.
Rubo J, Macpherson H, Young A. Atypical antipsychotics and other therapeutic options for treatment of resistant major depressive disorder. Pharmaceuticals. 2010;3:3522–42.CrossRef
10.
Garcia-Toro M, Medina E, Galan JL, Gonzalez MA, Maurino J. Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. BMC Psychiatry. 2012;12:143.CrossRefPubMedPubMedCentral
11.
Lamy FX, Chollet J, Clay E, Brignone M, Rive B, Saragoussi D. Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis. Curr Med Res Opin. 2015;31(4):795–807.CrossRefPubMed
12.
Saragoussi D, Chollet J, Bineau S, Chalem Y, Milea D. Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) study. Int J Clin Pract. 2012;66(11):1079–87.
13.
Sicras-Mainar A, Maurino J, Cordero L, Blanca-Tamayo M, Navarro-Artieda R. Assessment of pharmacological strategies for management of major depressive disorder and their costs after an inadequate response to first-line antidepressant treatment in primary care. Ann General Psychiatry. 2012;11(1):22.CrossRef
14.
Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008;63(7):699–704.CrossRefPubMed
15.
Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 6):16–25.CrossRefPubMed
16.
Trivedi MH, Morris DW, Wisniewski SR, Lesser I, Nierenberg AA, Daly E, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013;170(6):633–41.CrossRefPubMed
17.
18.
Guy W. Clinical global impressions. ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health; 1976.
19.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.CrossRefPubMed
20.
Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89–95.CrossRefPubMed
21.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–65.CrossRefPubMed
22.
McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. The Arizona sexual experience scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26(1):25–40.CrossRefPubMed
23.
Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.CrossRef
24.
EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRef
25.
26.
Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin. 2009;25(1):161–75.CrossRefPubMed
27.
Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther. 2013;35(2):177–88.CrossRef
28.
Santaguida PL, MacQueen G, Keshavarz H, Levine M, Beyene J, Raina P. Treatment for depression after unsatisfactory response to SSRIs. AHRQ publication no.12-EHC050-EF. Rockville: Agency for Healthcare Research and Quality; 2012.
29.
Simon GE, Revicki D, Heiligenstein J, Grothaus L, VonKorff M, Katon WJ, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry. 2000;22(3):153–62.CrossRefPubMed
30.
Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–41.CrossRefPubMed
31.
Thase ME, Pritchett YL, Ossanna MJ, Swindle RW, Xu J, Detke MJ. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol. 2007;27(6):672–6.CrossRefPubMed
32.
Vergouwen AC, Burger H, Koerselman F, Verheij TJ. Initial rate of improvement in relation to remission of major depressive disorder in primary care. Prim Care Companion J Clin Psychiatry. 2007;9(5):364–6.
33.
Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al.; STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354(12):1231–42.
34.
Lenderking W, Samp J, Hanlon J, Hsieh R, Revicki DA, Akhras KS. Adherence, switching and discontinuation during the 12 weeks following antidepressant initiation in patients with depressive disorder: results of a prospective longitudinal study. Value Health. 2013;16(7):A550.
35.
Köhler S, Unger T, Hoffmann S, Mackert A, Ross B, Fydrich T. The relationship of health-related quality of life and treatment outcome during inpatient treatment of depression. Qual Life Res. 2015;24(3):641–9.CrossRefPubMed
36.
37.
Ware J, Kosinski M, Keller SK. SF-36® physical and mental health summary scales: a user’s manual. Boston: The Health Institute; 1994.
38.
Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008;65(8):870–80.
39.
Schultz J, Joish V. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatr Serv. 2009;60(12):1604–11.CrossRefPubMed
40.
Sheffield RE, Lo Sasso AT, Young CH, Way K. Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization. Admin Policy Ment Health. 2002;30(2):121–39.CrossRef
41.
Beck A, Crain AL, Solberg LI, Unützer J, Glasgow RE, Maciosek MV, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9(4):305–11.CrossRefPubMedPubMedCentral
42.
Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004;2:20.CrossRefPubMedPubMedCentral
43.
Elliott TE, Renier CM, Palcher JA. Chronic pain, depression, and quality of life: correlations and predictive value of the SF-36. Pain Med. 2003;4(4):331–9.CrossRefPubMed
44.
Jiao J, Vincent A, Cha SS, Luedtke CA, Oh TH. Relation of age with symptom severity and quality of life in patients with fibromyalgia. Mayo Clin Proc. 2014;89(2):199–206.CrossRefPubMed
45.
Novick D, Montgomery W, Kadziola Z, Moneta V, Peng X, Brugnoli R, Haro JM. Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity? Patient Prefer Adherence. 2013;7:463–70.CrossRefPubMedPubMedCentral
46.
Soriano-Maldonado A, Amris K, Ortega FB, Segura-Jiménez V, Estévez-López F, Álvarez-Gallardo IC, et al. Association of different levels of depressive symptoms with symptomatology, overall disease severity, and quality of life in women with fibromyalgia. Qual Life Res. 2015;24(12):2951–7.CrossRefPubMed
47.
Castillo RC, Wegener ST, Heins SE, Haythornthwaite JA, Mackenzie EJ, Bosse MJ; LEAP study group. Longitudinal relationships between anxiety, depression, and pain: results from a two-year cohort study of lower extremity trauma patients. Pain. 2013;154(12):2860–6.CrossRefPubMed
48.
Means-Christensen AJ, Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB. Relationships among pain, anxiety, and depression in primary care. Depress Anxiety. 2008;25(7):593–600.CrossRefPubMed
49.
Fava M, Rush AJ, Alpert JE, Carmin CN, Balasubramani GK, Wisniewski SR, et al. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatr. 2006;51(13):823–35.CrossRef
50.
Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat. 2015;11:875–88.PubMedPubMedCentral
51.
Boyd A, Van de Velde S, Vilagut G, de Graaf R, O’Neill S, Florescu S, et al. Gender differences in mental disorders and suicidality in Europe: results from a large cross-sectional population-based study. J Affect Disord. 2015;173:245–54.CrossRefPubMed
52.
Trivedi MH, Rush AJ, Wisniewski SR, Warden D, McKinney W, Downing M. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006;67(2):185–95.CrossRefPubMed
53.
Andresen R, Caputi P, Oades LG. Do clinical outcome measures assess consumer-defined recovery? Psychiatry Res. 2010;177(3):309–17.CrossRefPubMed
54.
IsHak WW, Mirocha J, Pi S, Tobia G, Becker B, Peselow ED, Cohen RM. Patient-reported outcomes before and after treatment of major depressive disorder. Dialogues Clin Neurosci. 2014;16(2):171–83.PubMedPubMedCentral
55.
56.
Oliveira-Maia AJ, Mendonça C, Pessoa MJ, Camacho M, Gago J. The mental health recovery measure can be used to assess aspects of both customer-based and service-based recovery in the context of severe mental illness. Front Psychol. 2016;7:1679.CrossRefPubMedPubMedCentral
57.
Kovess-Masfety V, Alonso J, Brugha TS, Angermeyer MC, Haro JM, Sevilla-Dedieu C; ESEMeD/MHEDEA 2000 investigators. Differences in lifetime use of services for mental health problems in six European countries. Psychiatr Serv. 2007;58(2):213–20.CrossRefPubMed
Metadata
Title
Characteristics of patients with depression initiating or switching antidepressant treatment: baseline analyses of the PERFORM cohort study
Authors
Josep Maria Haro
François-Xavier Lamy
Bengt Jönsson
Martin Knapp
Mélanie Brignone
Hugo Caillou
Ylana Chalem
Lene Hammer-Helmich
Benoît Rive
Delphine Saragoussi
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2018
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-018-1657-3

Other articles of this Issue 1/2018

BMC Psychiatry 1/2018 Go to the issue

Research article

The future disposition Inventory-24: reliability and validity estimates in a large sample of Chinese University students

Research article

Health-related quality of life in prisoners with attention-deficit hyperactivity disorder and head injury

Research article

Resilience and burden in caregivers of older adults: moderating and mediating effects of perceived social support

Research article

Trauma exposure and the mediating role of posttraumatic stress on somatic symptoms in civilian war victims

Research article

The moderating roles of bedtime activities and anxiety/depression in the relationship between attention-deficit/hyperactivity disorder symptoms and sleep problems in children

Research article

Implementing prevention of seasonal affective disorder from patients’ and physicians’ perspectives – a qualitative study